rev bras hematol hemoter. 2017;39(1):93–94
w w w . r b h h . o r g
Revista
Brasileira
de
Hematologia
e
Hemoterapia
Brazilian
Journal
of
Hematology
and
Hemotherapy
Erratum
Erratum
to
“Diagnosis
and
treatment
of
chronic
lymphocytic
leukemia:
Recommendations
from
the
Brazilian
Group
of
Chronic
Lymphocytic
Leukemia”
[Rev
Bras
Hematol
Hemoter.
2016;38(4):346–357]
Celso
Arrais
Rodrigues
a,b,∗,
Matheus
Vescovi
Gonc¸alves
a,c,
Maura
Rosane
Valério
Ikoma
d,
Irene
Lorand-Metze
e,
André
Domingues
Pereira
b,
Danielle
Leão
Cordeiro
de
Farias
f,
Maria
de
Lourdes
Lopes
Ferrari
Chauffaille
a,c,
Rony
Schaffel
g,
Eduardo
Flávio
Oliveira
Ribeiro
h,
Talita
Silveira
da
Rocha
i,j,
Valeria
Buccheri
k,
Yuri
Vasconcelos
l,
Vera
Lúcia
de
Piratininga
Figueiredo
m,
Carlos
Sérgio
Chiattone
j,n,
Mihoko
Yamamoto
a,
on
behalf
of
the
Brazilian
Group
of
Chronic
Lymphocytic
Leukemia
aUniversidadeFederaldeSãoPaulo(UNIFESP),SãoPaulo,SP,Brazil
bHospitalSírioLibanês,SãoPaulo,SP,Brazil
cFleuryMedicinaeSaúde,SãoPaulo,SP,Brazil
dHospitalAmaralCarvalho,Jaú,SP,Brazil
eUniversidadeEstadualdeCampinas(UNICAMP),SãoPaulo,SP,Brazil
fUniversidadeFederaldeGoiás(UFG),Goiânia,GO,Brazil
gUniversidadeFederaldoRiodeJaneiro(UFRJ),RiodeJaneiro,RJ,Brazil
hHospitalSantaLúcia,Brasília,DF,Brazil
iA.CCamargoCancerCenter,SãoPaulo,SP,Brazil
jSantaCasadeMisericórdiadeSãoPaulo,SãoPaulo,SP,Brazil
kInstitutodoCâncerdoEstadodeSãoPaulo(ICESP),SãoPaulo,SP,Brazil
lInstitutoGoianodeOncologiaeHematologia(INGOH),Goiânia,GO,Brazil
mInstitutodeAssistênciaMédicaaoServidorPúblicoEstadual(IAMSPE),SãoPaulo,SP,Brazil
nHospitalSamaritano,SãoPaulo,SP,Brazil
Inthearticle“Diagnosis andtreatment ofchronic lympho-cyticleukemia:recommendations fromtheBrazilianGroup of Chronic Lymphocytic Leukemia”, published in Rev Bras HematolHemoter2016;38:346–57,pleaseconsiderthe follow-ingcorrection:
DOIoforiginalarticle:http://dx.doi.org/10.1016/j.bjhh.2016.07.004.
∗ Correspondingauthorat:UniversidadeFederaldeSãoPaulo(UNIFESP),RuaDoutorDiogodeFaria,824,VilaClementino,04037-002São
Paulo,SP,Brazil.
E-mailaddress:celsoarrais@gmail.com(C.A.Rodrigues).
2)Relapsedfirst-linetreatment:
a) Progressafter24months:repeatfirst-linetreatment(add ananti-CD20antibodyifnotusedinthefirst-line treat-ment)
http://dx.doi.org/10.1016/j.bjhh.2017.01.002
94
revbrashematolhemoter.2017;39(1):93–94b) Progresswithin24months: - ‘Go-go’patients:ibrutinib
• Alternativeoptions:venetoclax,alemtuzumabwithor
withoutmethylprednisolone,rituximabwithor with-outhigh-dose methylprednisolone,allogeneic HCST, bendamustineplusrituximab
- ‘Slow-go’patients:ibrutinib
• Alternative options: idelalisib plusrituximab,
